14:53:30 EST Mon 19 Nov 2018
Enter Symbol
or Name
USA
CA



Q:GILD - Gilead Sciences, Inc. - http://www.gilead.com14:53:30 EST
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
GILD - Q0.168.02 · 68.030.368.01-1.19-1.75,328.5364,52545,19269.10  69.24  67.6589.54  64.2714:33:03Nov 1815 min RT 2¢

Recent Trades - Last 10 of 45192
Time ETExPriceChangeVolume
14:33:11Q68.01-1.19100
14:33:11Q68.01-1.199
14:33:11Q68.01-1.1980
14:33:10Q68.01-1.19100
14:33:10Q68.01-1.19100
14:33:10Q68.01-1.19100
14:33:10Q68.01-1.19100
14:33:09Q68.011-1.18967
14:33:09Q68.011-1.1898
14:33:09Q68.015-1.185100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2018-11-18 22:00U:GILDNews ReleaseChina National Medical Products Administration (NMPA) Approves Gilead ’s Vemlidy ® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) Infection
2018-11-12 17:01U:GILDNews ReleaseGilead Sciences to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27
2018-11-09 08:00U:GILDNews ReleaseGilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting ® 2018
2018-11-09 08:00U:GILDNews ReleaseGilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting ® 2018
2018-11-09 08:00U:GILDNews ReleaseGilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting ® 2018
2018-11-01 09:00U:GILDNews ReleaseGilead to Present Latest Scientific Research in Hematologic Malignancies and Solid Tumors at ASH 2018
2018-10-31 08:30U:GILDNews ReleaseGilead Sciences and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies
2018-10-31 07:55U:GILDNews ReleaseInvestor Expectations to Drive Momentum within Gilead Sciences, SCANA, Brink's, Fortive, Asbury Automotive Group, and Helmerich & Payne — Discovering Underlying Factors of Influence
2018-10-30 06:36U:GILDNews ReleaseGilead Announces 96-Week Results From Phase 3 Study of Biktarvy ® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy
2018-10-25 16:02U:GILDNews ReleaseGilead Sciences Announces Fourth Quarter 2018 Dividend
2018-10-25 16:01U:GILDNews ReleaseGilead Sciences Announces Third Quarter 2018 Financial Results